STOK - Stoke Debt to Book Capitalization Ratio

Brandmark of Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics (STOK) lacks stable revenue streams, as its financial position at the 0.01 level depends on external funding. The company is mitigating risks by developing drugs to combat vision pathologies and epilepsy. This daily price chart reflects the price action, highlighting the scaling potential of RNA therapy, which, upon regulatory approval, could secure global leadership and high margins for the firm.

Debt to Book Capital: Stoke Therapeutics (STOK) for 07/04/2022 - 10/27/2026

Metric breakdowns and analytics for Stoke Therapeutics Inc (STOK)

- price and consensus price forecast:
Stock Price Stoke Therapeutics|STOK - Analyst Consensus Forecast
- market capitalization data:
Market Value Stoke Corp|STOK - Company Buyout Price
- book capitalization data:
Accounting Value per Share Stoke Therapeutics|STOK - Total Net Assets|Market Value to Book Value Ratio stoketherapeutics.com|STOK - Company Assets
- debt and liquidity data:
Debt to Equity Stoke Therapeutics|STOK - Long-Term Debt to Capital|Short-Term Debt to Capital Stoke|STOK - Company Cumulative Debt|Debt to Book Value Stoke Corp
Analysis of all company metrics:STOK, Stoke Therapeutics
Product sample of Stoke Therapeutics Inc

This indicator measures the share of total liabilities within the balance sheet capital structure, allowing for an assessment of financial leverage and the risk of over-indebtedness. By analyzing the ratio of total debt to book capitalization, an investor can confirm the stability of Stoke Therapeutics (STOK), whose management effectively funds gene therapy development by attracting investment capital while minimizing reliance on borrowed funds.

Competitors of Stoke Therapeutics (STOK)

Debts to Book Capitalization TEM (Tempus AI Inc)|qiagen.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio IONS (Ionis)|Repligen Corp (RGEN) - Debts to Net Assets|RNA - Debt to Book Value|CRSP (CRISPR) - Debt to Book Capital|Debt to Book Capitalization Ratio WGS (GeneDx Holdings Corp.)|Debts to Book Value RARE|Debt to Book Capitalization Ratio BEAM|Debts to Book Capitalization Sarepta Therapeutics (SRPT)|TWST: Debts to Book Capitalization|TXG - Debts to Book Value|Debt to Book Value Intellia Therapeutics (NTLA)|biolifesolutions.com (BLFS) - Debt to Net Assets Ratio|WVE - Debt to Book Value|Maze Therapeutics, Inc. (MAZE) - Debt to Book Capital|SION - Debts to Book Capitalization|Debt to Net Assets Ratio Prime Medicine Bio|Taysha Gene Therapies - Debts to Book Capitalization|Debts to Book Value QURE (uniqure.com)|Debt to Book Capitalization Ratio MeiraGTx|Debt to Net Assets Ratio REGENXBIO Inc RGNX|Solid Bio - Debts to Book Capitalization|OCGN: Debts to Book Capitalization|Debt to Book Capitalization Ratio Pacific Biosciences (PACB)|benitec.com (BNTC) - Debts to Book Capitalization Ratio|Debts to Book Capitalization DSGN (Design Therapeutics, Inc.)|Debts to Book Value Rocket Pharma (RCKT)|Debt to Book Value FDMT|Debts to Book Capitalization lexeotx.com LXEO|Debt to Book Value Korro Bio (KRRO)|Debt to Book Capital editasmedicine.com EDIT|Debts to Book Capitalization SLN (Silence Therapeutics plc)|PRQR - Debts to Net Assets|CDXS (codexis.com) - Debts to Book Capitalization|SGMO (Sangamo BioSciences) - Debt to Book Value|NAUT: Debt to Book Capitalization Ratio|Debts to Net Assets MGX|DTIL (Precision BioSciences, Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets generationbio.com GBIO|Debt to Book Value Boundless Bio, Inc (BOLD)|Exicure Inc. - Debt to Book Capital|IMNN (Celsion Corporation) - Debt to Book Capitalization Ratio|PHIO: Debts to Book Value|MBIO: Debt to Book Capitalization Ratio|TransCode Therapeutics, Inc. (RNAZ) - Debts to Book Capitalization|Debts to Book Capitalization Bionano Genomics Inc. (BNGO)|Debt to Book Value Ratio APDN|Debt to Book Capitalization Ratio bluebird bio, Inc. BLUE|Debt to Book Value Ratio immunoprecise.com (IPA)|Debts to Book Capitalization OMGA (Omega Therapeutics, Inc.)|Singular Genomics Systems, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio RGLS (Regulus Therapeutics Inc)|Syros Pharmaceuticals, Inc (SYRS) - Debts to Net Assets|TBIO - Debt to Book Value|TCON (traconpharma.com) - Debt to Book Capital|Debt to Book Capitalization Ratio UBX (Unity Biotechnology, Inc.)